Daniel Yokell is an experienced Associate Director in Regulatory Affairs, specializing in the cGMP Radiopharmaceutical Industry for over 12 years. Currently serving as the Head of Diagnostic Neuro-Oncology at Telix Pharmaceuticals Limited, they lead the company's neuro-oncology portfolio. Previously, Daniel managed the MGH PET Radiopharmacy at Massachusetts General Hospital, overseeing regulatory affairs and the operations of a high-volume PET manufacturing facility. They also held instructional roles at Harvard Medical School and provided consulting services on PET regulatory matters. Daniel is a Board Certified Nuclear Pharmacist and holds a PharmD from Northeastern University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices